134 related articles for article (PubMed ID: 11157040)
1. Phase I and pharmacokinetic study of LU79553, a DNA intercalating bisnaphthalimide, in patients with solid malignancies.
Villalona-Calero MA; Eder JP; Toppmeyer DL; Allen LF; Fram R; Velagapudi R; Myers M; Amato A; Kagen-Hallet K; Razvillas B; Kufe DW; Von Hoff DD; Rowinsky EK
J Clin Oncol; 2001 Feb; 19(3):857-69. PubMed ID: 11157040
[TBL] [Abstract][Full Text] [Related]
2. A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies.
Villalona-Calero MA; Eckhardt SG; Weiss G; Hidalgo M; Beijnen JH; van Kesteren C; Rosing H; Campbell E; Kraynak M; Lopez-Lazaro L; Guzman C; Von Hoff DD; Jimeno J; Rowinsky EK
Clin Cancer Res; 2002 Jan; 8(1):75-85. PubMed ID: 11801542
[TBL] [Abstract][Full Text] [Related]
3. DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
Rowinsky EK; Johnson TR; Geyer CE; Hammond LA; Eckhardt SG; Drengler R; Smetzer L; Coyle J; Rizzo J; Schwartz G; Tolcher A; Von Hoff DD; De Jager RL
J Clin Oncol; 2000 Sep; 18(17):3151-63. PubMed ID: 10963644
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties.
Tolcher AW; Eckhardt SG; Kuhn J; Hammond L; Weiss G; Rizzo J; Aylesworth C; Hidalgo M; Patnaik A; Schwartz G; Felton S; Campbell E; Rowinsky EK
J Clin Oncol; 2001 Jun; 19(11):2937-47. PubMed ID: 11387367
[TBL] [Abstract][Full Text] [Related]
5. A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies.
Schwartz G; Johnson TR; Goetz A; Burris H; Smetzer L; Lampkin T; Sailstad J; Hohneker JA; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 2001 Jul; 7(7):1901-11. PubMed ID: 11448903
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules.
Rowinsky EK; Noe DA; Grochow LB; Sartorious SE; Bowling MK; Chen TL; Lubejko BG; Kaufmann SH; Donehower RC
J Clin Oncol; 1995 Aug; 13(8):1975-84. PubMed ID: 7636538
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.
Herben VM; van Gijn R; Schellens JH; Schot M; Lieverst J; Hillebrand MJ; Schoemaker NE; Porro MG; Beijnen JH; ten Bokkel Huinink WW
J Clin Oncol; 1999 Jun; 17(6):1906-14. PubMed ID: 10561232
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.
Eckhardt SG; Baker SD; Britten CD; Hidalgo M; Siu L; Hammond LA; Villalona-Calero MA; Felton S; Drengler R; Kuhn JG; Clark GM; Smith SL; MacDonald JR; Smith C; Moczygemba J; Weitman S; Von Hoff DD; Rowinsky EK
J Clin Oncol; 2000 Dec; 18(24):4086-97. PubMed ID: 11118470
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of bizelesin, a highly potent and selective DNA-interactive agent, in patients with advanced solid malignancies.
Schwartz GH; Patnaik A; Hammond LA; Rizzo J; Berg K; Von Hoff DD; Rowinsky EK
Ann Oncol; 2003 May; 14(5):775-82. PubMed ID: 12702533
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
[TBL] [Abstract][Full Text] [Related]
11. A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies.
Villalona-Calero MA; Petit T; Kuhn J; Cobb P; Kraynak M; Eckhardt SG; Drengler R; Simmons C; Santabarbara P; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1999 Nov; 5(11):3369-78. PubMed ID: 10589747
[TBL] [Abstract][Full Text] [Related]
12. Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
de Bono JS; Stephenson J; Baker SD; Hidalgo M; Patnaik A; Hammond LA; Weiss G; Goetz A; Siu L; Simmons C; Jolivet J; Rowinsky EK
J Clin Oncol; 2002 Jan; 20(1):96-109. PubMed ID: 11773159
[TBL] [Abstract][Full Text] [Related]
13. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.
Rowinsky EK; Grochow LB; Sartorius SE; Bowling MK; Kaufmann SH; Peereboom D; Donehower RC
J Clin Oncol; 1996 Apr; 14(4):1224-35. PubMed ID: 8648378
[TBL] [Abstract][Full Text] [Related]
15. An EORTC-ECSG phase I study of LU 79553 administered every 21 or 42 days in patients with solid tumours.
Awada A; Thödtmann R; Piccart MJ; Wanders J; Schrijvers AH; Von Broen IM; Hanauske AR;
Eur J Cancer; 2003 Apr; 39(6):742-7. PubMed ID: 12651198
[TBL] [Abstract][Full Text] [Related]
16. A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies.
Faivre S; Raymond E; Boige V; Gatineau M; Buthaut X; Rixe O; Bernareggi A; Camboni G; Armand JP
Clin Cancer Res; 2001 Jan; 7(1):43-50. PubMed ID: 11205916
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors.
Ebbinghaus S; Rubin E; Hersh E; Cranmer LD; Bonate PL; Fram RJ; Jekunen A; Weitman S; Hammond LA
Clin Cancer Res; 2005 Nov; 11(21):7807-16. PubMed ID: 16278403
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies.
Villalona-Calero MA; Weiss GR; Burris HA; Kraynak M; Rodrigues G; Drengler RL; Eckhardt SG; Reigner B; Moczygemba J; Burger HU; Griffin T; Von Hoff DD; Rowinsky EK
J Clin Oncol; 1999 Jun; 17(6):1915-25. PubMed ID: 10561233
[TBL] [Abstract][Full Text] [Related]
19. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
Dees EC; Whitfield LR; Grove WR; Rummel S; Grochow LB; Donehower RC
Clin Cancer Res; 2000 Oct; 6(10):3885-94. PubMed ID: 11051234
[TBL] [Abstract][Full Text] [Related]
20. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.
Rinaldi DA; Kuhn JG; Burris HA; Dorr FA; Rodriguez G; Eckhardt SG; Jones S; Woodworth JR; Baker S; Langley C; Mascorro D; Abrahams T; Von Hoff DD
Cancer Chemother Pharmacol; 1999; 44(5):372-80. PubMed ID: 10501910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
